MaxCyte Partnership Portfolio

August 12, 2026




MaxCyte® expert® ATx® STx® GTx® VLx® DTx® are trademarks of MaxCyte, Inc. in the U.S.A.

© 2026 MaxCyte, Inc. All Rights Reserved

MaxCyte has an Active Portfolio of SPLs

- cGMP Compatible Platform
- FDA Master File and Technical Files
- Experienced FAS and sales support
- Leading know-how and engineering process improvement



Updated as of August 2026

1. *Catamaran Bio and Walking Fish Therapeutics have ceased operations, resulting in 29 SPLs*
2. *Cleared INDs or Equivalent*
3. *Editas Medicine, Myeloid, and Vor Biopharma have announced their exit of the ex-vivo space*

12 Active Clinical Programs Represents ~$110M of precommercial milestone potential
>$30M of milestone payments to date through SPL model

© 2026 MaxCyte, Inc. All Rights Reserved

SPL Portfolio: 14 Active Clinical Trials

Partner	Program	Phase	Cell Approach	Cell Type	Disease Area
Vertex Pharmaceuticals	CASGEVY	Commercial	Autologous	HSCs	Beta-thalassemia
Vertex Pharmaceuticals	CASGEVY	Commercial	Autologous	HSCs	Sickle cell disease
Wugen	WU-CART-007	Pivotal	Allogeneic	T-Cells	T Cell Lymphoma
Undisclosed Partner A	-	Pivotal	Undisclosed	Undisclosed	Undisclosed
CRISPR Therapeutics	CTX112	1/2	Allogeneic	T-Cells	Hematological Malignancies
CRISPR Therapeutics	CTX112	1/2	Allogeneic	T-Cells	Autoimmune Disease
Imugene	Azer-cel	1/2	Allogeneic	T-Cells	Hematological Malignancies
Kamau Therapeutics	Nula-Cel	1/2	Autologous	HSCs	Sickle Cell Disease
KSQ Therapeutics	KSQ-001EX	1/2	Autologous	TILs	Advanced Solid Tumors
KSQ Therapeutics	KSQ-004EX	1/2	Autologous	TILs	Advanced Solid Tumors
TG Therapeutics	Azer-cel	1	Allogeneic	T-Cells	Multiple Sclerosis
Vittoria Biotherapeutics	VIPER-101	1	Autologous	T-Cells	T-Cell Lymphoma
Undisclosed Partner B	-	1	Undisclosed	Undisclosed	Undisclosed
Undisclosed Partner C	-	1	Undisclosed	Undisclosed	Undisclosed

As of June 2026 / Includes with SPL Programs with multiple Clinical Trials for different indications


© 2026 MaxCyte, Inc. All Rights Reserved

Expanding Opportunity: Growth in Therapeutic Areas and Clinical SPL Programs

SPL Trials Across Multiple Therapeutic Areas

Therapeutic Area	Clinical/ Commercial	Pre-Clinical
Genetic Disease	5	1
Blood Cancer	4	0
Solid Tumor	3	14
Autoimmune Disease	2	0
Neurodegenerative Disease	0	2
Total	**14**	**17**

SPL Programs (Clinical & Commercial)



© 2026 MaxCyte, Inc. All Rights Reserved

MaxCyte Supports the Future of Cell & Gene Therapies

WAVE 1	WAVE 2	WAVE 3	WAVE 4
1 Approved Product	5 Product Candidates	7 Product Candidates	17 Product Candidates
Vertex/ CRISPR CASGEVY® **Approved 2023** **US FDA, European Commission & Additional Regulatory Bodies**	**Launch Potential: 2027 – 2028** **5 products set to enter pivotal studies in next 6 to 18 months**	**Launch Potential: 2028 +** **7 products currently in Phase 1**	**Launch Potential: 2032 +** **17 products in preclinical development**

MaxCyte's supports a diverse portfolio of product candidates with significant development milestone and commercial royalty potential

Source: Evaluate Pharma, Broker Estimates and MaxCyte Internal Estimates as of June 2026

© 2026 MaxCyte, Inc. All Rights Reserved

Second Wave Set to Enter Pivotal Studies in Next 6 to 18 Months


SPL	Clinical Programs	Phase	Cell Type	Cell Approach	Indication
CRISPR THERAPEUTICS	CTX112	1/2	T-cells	Allogeneic	B-cell Malignancies
Wugen	WU-CART-007	Pivotal	T-cells	Allogeneic	Hematologic Malignancies
IMUGENE	Azer-Cel	1/1b	T-Cells	Allogeneic	Hematologic Malignancies
Undisclosed	*Undisclosed Program*	1	*Undisclosed*	*Undisclosed*	*Undisclosed*
Undisclosed	*Undisclosed Program*	Pivotal	*Undisclosed*	*Undisclosed*	*Undisclosed*

© 2026 MaxCyte, Inc. All Rights Reserved

Illustrative Revenue Profile for a Successful SPL Program

Revenue Growth Drivers: Significant development milestones and high-value participation in future commercial success of partners' programs

Assumptions: First Approval in Year 7 | Approval in Three Geographic Regions
$1.0B Peak Sales | Peak Sales Commercial Year 7 | Royalty 1.0%



© 2026 MaxCyte, Inc. All Rights Reserved

Genentech Partnership

Multi-Platform Technology License Partnership

An enterprise-level relationship providing Genentech access to MaxCyte's ExPERT™ GTx® platform and additional platform technologies across research, clinical development, and commercial manufacturing workflows

Enterprise Framework

Structured to support Genentech's cell therapy portfolio under a single relationship — not on a product-by-product basis

Platform Access

ExPERT™ GTx® plus complementary technologies spanning non-viral cell engineering and analytical assessment

Full Lifecycle

Integrated support for ex vivo cell engineering from early discovery through cGMP manufacturing

Portfolio Scale

Enables broad platform adoption across multiple development programs rather than individual assets

MaxCyte is Supporting Genentech's Active Cell & Gene Therapy Portfolio

© 2026 MaxCyte, Inc. All Rights Reserved

An Expanding Partnering Model for Large Pharma

Enterprise partnerships complement MaxCyte's Strategic Platform License (SPL) model

Strategic Platform License (SPL)

Product-by-product

- Non-exclusive license to ExPERT™ platform for biotechs developing individual therapeutic programs
- An attractive solution for biotechnology customers developing individual programs
- Annual license fees and milestones in clinical development, plus royalties on net sales at commercialization

Enterprise Partnership (Example: Genentech)

Portfolio-wide

- Enterprise-level relationship designed to support a pharma's cell therapy portfolio (access to EXPERT™ platform & analytical assessment services)
- An additional commercial model that expands MaxCyte's addressable market among large pharma organizations
- Recurring license and platform-access revenue with earlier monetization, milestone opportunities, and risk-adjusted economics comparable to an SPL

The enterprise model expands MaxCyte's commercial toolkit while preserving the value proposition of the existing SPL portfolio

© 2026 MaxCyte, Inc. All Rights Reserved

Thank you!
Any questions?

ir@maxcyte.com

©2025 MaxCyte, Inc. All rights reserved. For a complete list of MaxCyte trademarks in the United States and other countries, please visit **maxcyte.com/trademarks**.

All other trademarks are the property of their respective owners.

© 2026 MaxCyte, Inc. All Rights Reserved